130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
"HIV Preventive Vaccine" [CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Interventions: Biological: HIVAC-1e;   Biological: gp160 Vaccine (MicroGeneSys)
3 Unknown  Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers
Condition: HIV Infections
Intervention: Biological: SCBaL/M9
4 Completed Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
Condition: HIV Infections
Intervention: Biological: VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
5 Completed ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1;   Biological: ALVAC(2)120(B,MN)GNP (vCP1452) placebo;   Biological: MN rgp120/HIV-1  placebo
6 Completed Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults
Condition: HIV Infections
Interventions: Biological: EP-1233;   Biological: MVA-mBN32
7 Completed Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
Condition: HIV Infections
Interventions: Biological: HIV CTL MEP administered with RC529-SE adjuvant;   Drug: GM-CSF
8 Completed A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Condition: HIV Infections
Intervention: Biological: gp160 Vaccine (Immuno-AG)
9 Completed A Phase I Safety and Immunogenicity Trial of the Facilitated HIV-1 Gag-Pol DNA Vaccine (APL-400-047, Apollon, Inc.) Given Intramuscularly by Needle and Syringe or Biojector 2000 Needle-Free Jet Injection System in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: APL 400-047;   Drug: Bupivacaine hydrochloride
10 Completed Expanded Characterization of Immune Response to Merck Adenovirus 5 Gag/Pol/Nef Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: MRKAd5 HIV-1 gag/pol/nef
11 Completed A Phase I Study of Safety and Immunogenicity of the WRAIR HIV-1 Vaccine LFn-p24 Administered by the Intramuscular (IM) Route in Healthy Adults
Condition: HIV Infections
Intervention: Biological: HIV LFn-p24
12 Completed Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of VaxSyn Recombinant gp160 (NOTE: Some Patients Receive Placebo)
Conditions: HIV Infections;   Pregnancy;   HIV Seronegativity
Intervention: Biological: gp160 Vaccine (MicroGeneSys)
13 Active, not recruiting Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Condition: HIV Infections
Intervention: Biological: Ad5.ENVA.48 HIV-1 vaccine
14 Completed A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1;   Biological: ALVAC-HIV MN120TMG (vCP205)
15 Completed Safety and Immunogenicity Study of Candidate HIV-1 Vaccine Given to Healthy Infants Born to HIV-1/2-uninfected Mothers
Conditions: HIV-1;   HIV Infections
Intervention: Biological: MVA.HIVA
16 Active, not recruiting Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector
Condition: HIV Infections
Interventions: Biological: DNA Vaccine;   Biological: DNA Vaccine placebo;   Biological: rAd35;   Biological: rAd35 placebo;   Biological: rAd5;   Biological: rAd5 placebo
17 Completed A Phase I Study of Modified Vaccinia Virus Ankara (MVA-B) in Healthy Volunteers at Low Risk of HIV Infection
Condition: HIV Infections
Interventions: Biological: MVA-B;   Biological: Placebo
18 Completed Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults
Condition: HIV Infection
Intervention: Biological: ADMVA
19 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
20 Completed Safety of the EnvPro HIV Vaccine in Healthy Volunteers
Condition: HIV Infections
Intervention: Biological: EnvPro

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years